20/20 Biolabs financials
$0.1869−18.35%
Close Nov 5, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $730.6K | $353.4K |
| Gross profit | $304.7K | $62.9K |
| Gross margin | 41.7% | 17.8% |
| Operating income | -$1.2M | -$1.4M |
| Net income | -$2.8M | -$2.1M |
| Net margin | −376.8% | −600.1% |
| Diluted EPS | $-0.26 | $-0.28 |
| EBITDA | -$1.2M | -$1.4M |
| Operating cash flow | -$605.5K | -$1.3M |
| Free cash flow | -$605.5K | -$1.3M |
| Diluted shares | 10.8M | 7.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $4.5M | $4.2M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $306.7K |
| Total assets | $6.1M | $5.8M |
| Total liabilities | $3.0M | $3.0M |
| Shareholders' equity | $1.6M | $2.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology